Voltaren®
Diclofenac sodium 0.1% · ophthalmic solution
NSAID
Approved uses
Postoperative inflammation after cataract extraction
1 drop QID beginning 24 hours after surgery, continuing through the first 2 postoperative weeks
Pain and photophobia after corneal refractive surgery
1 to 2 drops within the hour before surgery, 1 to 2 drops within 15 minutes after surgery, then QID for up to 3 days
Contraindications
Hypersensitivity to any component of the formulation.
0.1% (1 mg/mL) sterile solution, 5 mL fill in a 10 mL bottle
Phenylacetic acid NSAID that is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. In cataract patients, the drug was favored over vehicle placebo over a 2-week period for inflammation measured by anterior chamber cells and flare.
Warnings & Precautions
- Corneal adverse events: All topical NSAIDs may slow or delay healing, and use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use may result in epithelial breakdown, corneal thinning, corneal infiltrates, corneal erosion, corneal ulceration and corneal perforation, which may be sight-threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored for corneal health.
- Historical melt cases: In a review of 11 patients with corneal melting after topical 0.5% diclofenac ophthalmic solution, generic diclofenac (Falcon) was associated with 7 and Voltaren with 4, after 6 days to 17 months of treatment; the author concluded that the inconsistent and variable dose-toxicity relationships suggest that coexistent factors other than a simple drug toxicity are implicated, if not causative. This label covers a 0.1% solution.
- Increased risk for corneal adverse events: Postmarketing experience suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface disease (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight-threatening; use with caution in these patients.
- Severity of corneal adverse events: Postmarketing experience also suggests that use more than 24 hours before surgery or beyond 14 days after surgery may increase the occurrence and severity of corneal adverse events.
- Healing problems: Topical corticosteroids also slow or delay healing, so concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Increased bleeding time: With some NSAIDs there is the potential for increased bleeding time due to interference with thrombocyte aggregation, and there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery; use with caution in patients with known bleeding tendencies or receiving other medications which may prolong bleeding time.
- Cross-sensitivity: There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents, so caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
- Refractive stability: Not established in patients treated after corneal refractive procedures; monitor for one year following use in that setting.
- Adverse events with soft contact lenses: Except for a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, the drug should not be used by patients currently wearing soft contact lenses due to adverse events that have occurred in other circumstances.
- General Precautions: Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.
- Elevated intraocular pressure: Clinical studies indicate no significant effect upon ocular pressure, but elevations in intraocular pressure may occur following cataract surgery.
Common Side Effects
Transient burning and stinging were reported in approximately 15% of patients. In cataract surgery studies, keratitis was reported in up to 28%, though in many cases it was noted prior to the initiation of treatment. Elevated IOP after cataract surgery was reported in approximately 15%. Lacrimation complaints were reported in approximately 30% after incisional refractive surgery. Reactions in approximately 10% or less included abnormal or blurred vision, acute elevated IOP, conjunctivitis, corneal deposits, edema, opacity and lesions, discharge, eyelid swelling, eye pain, redness, iritis, irritation, itching, lacrimation disorder and ocular allergy. Systemic reactions in 3% or less included abdominal pain, asthenia, chills, dizziness, facial edema, fever, headache, insomnia, nausea, pain, rhinitis, viral infection and vomiting.
Pregnancy: Category C. No adequate, well-controlled studies in pregnant women; no teratogenicity in mice at oral doses up to 5,000 times, or in rats and rabbits up to 2,500 times, the human topical dose, despite maternal and fetal toxicity. Avoid in late pregnancy, since prostaglandin synthesis inhibitors can close the fetal ductus arteriosus. Otherwise use during pregnancy only if clearly needed.
Lactation: Unknown whether topical ophthalmic use produces detectable quantities in human milk; weigh continued nursing against the importance of the drug to the mother.
Safety and effectiveness in pediatric patients not established.